Zacks.com on MSN1 天
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Victory Capital Management Inc. Sells 346 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Victory Capital Management Inc. decreased its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 1.9% during the 4th quarter, Holdings Channel reports. The firm owned 18,004 shares ...
Nanowerk1 天
New battery material enables rapid charging in seconds
A newly engineered niobium battery material enables record-fast charging by optimizing lithium-ion movement at the atomic ...
Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded to Sell at StockNews.com
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...
Zacks Investment Research on MSN11 天
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
Ionis Pharmaceuticals IONS announced that the European Commission (“EC”) has approved Wainzua (eplontersen) for treating ...
Seeking Alpha8 天
IONS Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with ...
Ionis Pharmaceuticals (IONS) Receives a Buy from William Blair
William Blair analyst Myles Minter reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today. The company’s shares opened ...